CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Expert Perspectives on Current Challenges and Emerging Approaches for Multiple Myeloma: Narrative Review of an Inaugural Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma.
Expert Perspectives on Current Challenges and Emerging Approaches for Multiple Myeloma: Narrative Review of an Inaugural Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
在多发性骨髓瘤（MM）患者的管理方面，围绕风险评估、治疗选择与排序，以及在平衡疗效、毒性、患者因素和治疗流程的前提下如何最优使用现有疗法，仍存在许多争议。
多发性骨髓瘤（MM）的管理日趋复杂。新型治疗方案获批带来亟需的治疗机会，同时也引发关于如何优化治疗排序、为个体患者选择治疗的疑问。方法与结果：专家小组召开会议，讨论 MM 整个疾病进程中的当前治疗争议。研讨主题包括冒烟型 MM 管理、适合或不适合移植患者的治疗选择、风险评估及风险适配治疗的可能性、将可测量残留病（MRD）用作临床试验终点和指导治疗决策、早期复发管理、三类药物耐药 MM 管理、治疗顺序及新型疗法。
MM 患者管理仍有诸多争议，涉及风险评估、治疗选择与顺序，以及如何在平衡疗效、毒性、患者情况和治疗流程的同时优化当前治疗方案。仍需持续研究，以进一步明确当前疗法的最佳使用方式，并为所有患者及存在未满足需求的特定亚群开发更有效的疗法。
The management of multiple myeloma (MM) is becoming increasingly more complex. The approval of novel treatment approaches provides much-needed opportunities but also raises questions and controversies about how to optimally sequence therapies and select treatments for individual patients. METHODS AND RESULTS: A panel of experts assembled to discuss current controversies in the care of patients with MM across the disease continuum. Workshop topics included: management of smoldering MM; treatment selection for transplant-eligible and transplant-ineligible patients; risk assessment and the possibility of risk-adapted treatment; use of measurable residual disease (MRD) as a clinical trial end point and to guide treatment decisions; management of early relapse; management of triple class-refractory MM; treatment sequencing; and novel therapies.
Many controversies remain regarding the management of patients with MM related to risk assessment, treatment selection and sequencing, and the optimal use of current therapies while balancing efficacy, toxicity, patient considerations, and treatment logistics. Ongoing research efforts are needed to further define the optimal use of current therapies and to develop more efficacious therapies for all patients and for particular subset populations with unmet need.
MEMBER ACCOUNT
登录成功会直接打开下一页。
